ArticleLiver cancer2020
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.
Article in Liver cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Beyond side effects: treatment-related adverse events are associated with improved survival outcomes in HCC patients on atezolizumab-bevacizumab therapy.BMC cancer · 2026Trial
- Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial.Signal transduction and targeted therapy · 2025Trial
- Real-World Outcomes of Combined Carbon-Ion Radiotherapy and Systemic Immunotherapy for Hepatocellular Carcinoma (Atezolizumab Plus Bevacizumab or Durvalumab Plus Tremelimumab): A Single-Center Retrospective Study.Journal of clinical medicine · 2026Article
- Acquired Genetic Variants, Not Tumor Mutation Burden, Drive Resistance to Immunotherapy in Hepatocellular Carcinoma.Liver cancer · 2026Article
- Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma.Molecular diversity · 2026Article
- Transcription Factor Networks Drive Tumor Progression and Immune Microenvironment Remodeling in Hepatocellular Carcinoma.Cancers · 2025Article
- Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights.Liver research (Beijing, China) · 2025Review
- Tumor Rupture in a Patient with Recurrent Hepatocellular Carcinoma Following Atezolizumab plus Bevacizumab: A Case Report.Surgical case reports · 2025Article
- Efficacy and Safety Analysis of Transarterial Chemoembolization Combined with Sintilimab Plus Bevacizumab Biosimilar in the Treatment of Unresectable Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Review
- Programmable melanoma-targeted radio-immunotherapy via fusogenic liposomes functionalized with multivariate-gated aptamer assemblies.Nature communications · 2024Article
- Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma.iLIVER · 2024Review
- Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy.World journal of gastrointestinal oncology · 2023Article
- Article
- A contrast-enhanced ultrasound-based nomogram for the prediction of therapeutic efficiency of anti-PD-1 plus anti-VEGF agents in advanced hepatocellular carcinoma patients.Frontiers in immunology · 2023Article
- The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.Journal of hepatocellular carcinoma · 2023Article
- The Complement System: A Potential Therapeutic Target in Liver Cancer.Life (Basel, Switzerland) · 2022Review
- Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.Hepatobiliary surgery and nutrition · 2022Article
- First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.